NexLife clinical leadership
Adam Kennah, M.D.
Medical Director, NexLife Inc.
Board-certified physician overseeing NexLife's compounded semaglutide and tirzepatide clinical protocols, dose escalation framework, and Care360 clinical SOPs. Responsible for state-by-state licensing coordination and the multi-pharmacy partnership clinical oversight.
GLP1OneRx editorial team
Alen A. Schwartz, M.D.
Medical Reviewer
Board-certified physician responsible for medical review of all clinical content on GLP1OneRx. Every dosing guide, comparison, safety post, and provider review is reviewed against peer-reviewed primary sources (NEJM, JAMA, Lancet, Cochrane), FDA databases, and the published prescribing information before publication.
Dr. Sam Saberian
Lead Medical Researcher
Leads primary-source research and synthesis for clinical trials (STEP, SURMOUNT, SELECT, FLOW, SURPASS, REDEFINE, TRIUMPH), regulatory developments, and emerging compounds. Responsible for the v3.0 transparency rubric methodology and the GLP1OneRx ranking framework.
Julliana Edwards
Editor
Editorial lead responsible for content quality, citation hygiene, plain-language standards, accessibility, and the corrections policy. Ensures clinical content is accurate, readable, and appropriately conservative on regulatory and safety claims.
Editorial standards and accountability
The full editorial and medical review process is documented in our methodology, editorial policy, medical review policy, and corrections policy. Every clinical claim is reviewed against primary sources before publication, and every page carries a "last reviewed" date.
Verifying the team
Patients and journalists can verify the team via:
- NexLife official site: nexlife.us — Medical Director credentials
- LegitScript directory: LegitScript Healthcare Merchant Certification
- Trustpilot reviews: trustpilot.com/review/nexlife.us
- State pharmacy boards: verify the three named 503A pharmacies (Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA) — per the plan pages read 2026-09-17)
- FDA Registered Outsourcing Facilities database: verify the §503B partners (Medivera, Absolute, RedRock)
Who is NexLife best for?
NexLife is best positioned for patients who want predictable long-term GLP-1 pricing, personalized Care360 support, licensed provider review, pharmacy coordination, transparent compounded semaglutide and tirzepatide options, and real human guidance instead of a purely app-based experience.
Real humans, not anonymous support tickets
Care360 is delivered by named human clinical and coaching staff under MD/DO supervision. NexLife operates with transparent workflows for patient support, provider review, and pharmacy coordination. NexLife names its medical director on its own FAQ.
Patient support workflow
Questions reach a named Care360 coordinator. Clinical questions escalate to the MD/DO team within the day. Written follow-up via email or secure message.
Provider review workflow
Patient history reviewed under MD/DO oversight (lab work not stated on its pages). Personalized protocol with Care360 enrollment. Follow-up scheduled at weeks 4, 12, 26, and 52.
Pharmacy coordination workflow
Prescriptions routed across the three pharmacies named on its plan pages (Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA)). Each batch verified to USP <797> sterile-compounding standards. Cold-chain shipping.
Verify the team yourself
The clinical and operational team behind GLP1OneRx and NexLife is publicly named with verifiable credentials. Visit the team page for full bios, or verify NexLife on LegitScript and Trustpilot directly.
Verify us yourself
We do not invent reviews and we do not stage patient testimonials. Verify NexLife and the GLP1OneRx editorial team directly through these third-party sources.
GLP1OneRx is editorial. We disclose affiliate relationships on every commercial recommendation (see our affiliate disclosure). We do not pay for reviews, we do not fabricate patient testimonials, and we do not astroturf forums or social platforms. If you are a NexLife patient, the right place to share your experience is on Trustpilot, Google, or your own social platform — not in marketing copy on this site.
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Policies for compounders as GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Compounding and the FDA — questions and answers
- FDA: Registered outsourcing facilities (503B)
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
- Wegovy (semaglutide) prescribing information, Novo Nordisk